The increasing use of medicinal cannabis (MC) in the past decade raises several ethical considerations for the case manager. Regulatory issues stem from a gap not only in understanding varying state and federal regulations but also in maintaining a competent knowledge of adjunctive cannabis pharmacotherapy when a patient utilizes that therapy.